These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 24748496)

  • 21. Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML.
    Fein JA; Shouval R; Krieger E; Spellman SR; Wang T; Baldauf H; Fleischhauer K; Kröger N; Horowitz M; Maiers M; Miller JS; Mohty M; Nagler A; Weisdorf D; Malmberg KJ; Toor AA; Schetelig J; Romee R; Koreth J
    Blood Adv; 2024 Feb; 8(3):581-590. PubMed ID: 38052043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation.
    Cooley S; Parham P; Miller JS
    Blood; 2018 Mar; 131(10):1053-1062. PubMed ID: 29358179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation.
    Sekine T; Marin D; Cao K; Li L; Mehta P; Shaim H; Sobieski C; Jones R; Oran B; Hosing C; Rondon G; Alsuliman A; Paust S; Andersson B; Popat U; Kebriaei P; Muftuoglu M; Basar R; Kondo K; Nieto Y; Shah N; Olson A; Alousi A; Liu E; Sarvaria A; Parmar S; Armstrong-James D; Imahashi N; Molldrem J; Champlin R; Shpall EJ; Rezvani K
    Blood; 2016 Jul; 128(2):297-312. PubMed ID: 27247137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hematopoietic stem cell transplantation: killer immunoglobulin-like receptor component.
    Hsu KC; Pinto-Agnello C; Gooley T; Malkki M; Dupont B; Petersdorf EW
    Tissue Antigens; 2007 Apr; 69 Suppl 1():42-5. PubMed ID: 17445161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation.
    Weisdorf D; Cooley S; Wang T; Trachtenberg E; Vierra-Green C; Spellman S; Sees JA; Spahn A; Vogel J; Fehniger TA; Woolfrey AE; Devine SM; Ross M; Waller EK; Sobecks RM; McGuirk J; Oran B; Farag SS; Shore T; Van Besien K; Marsh SGE; Guethlein LA; Parham P; Miller JS
    Blood Adv; 2020 Feb; 4(4):740-754. PubMed ID: 32092137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of Differently Licensed KIR2DL1-Positive Natural Killer Cells in Transplant Recipients with Acute Leukemia: A Japanese National Registry Study.
    Arima N; Nakamura F; Yabe T; Tanaka J; Fuji S; Ohashi K; Fukuda T; Miyamura K; Iwato K; Eto T; Mori T; Kobayashi N; Hoshino T; Kato C; Kanamori H; Nakamae H; Atsuta Y; Morishima Y; Kanda Y
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):423-31. PubMed ID: 26456260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors.
    Sobecks RM; Ball EJ; Maciejewski JP; Rybicki LA; Brown S; Kalaycio M; Pohlman B; Andresen S; Theil KS; Dean R; Bolwell BJ
    Bone Marrow Transplant; 2007 Apr; 39(7):417-24. PubMed ID: 17310134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KIR and their HLA Class I ligands: Two more pieces towards completing the puzzle of chronic rejection and graft loss in kidney transplantation.
    Littera R; Piredda G; Argiolas D; Lai S; Congeddu E; Ragatzu P; Melis M; Carta E; Michittu MB; Valentini D; Cappai L; Porcella R; Alba F; Serra M; Loi V; Maddi R; Orrù S; La Nasa G; Caocci G; Cusano R; Arras M; Frongia M; Pani A; Carcassi C
    PLoS One; 2017; 12(7):e0180831. PubMed ID: 28686681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation.
    Rangarajan HG; Pereira MSF; Brazauskas R; St Martin A; Kussman A; Elmas E; Verneris MR; Gadalla SM; Marsh SGE; Paczesny S; Spellman SR; Lee SJ; Lee DA
    Transplant Cell Ther; 2021 Nov; 27(11):926.e1-926.e10. PubMed ID: 34407489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation.
    Boudreau JE; Giglio F; Gooley TA; Stevenson PA; Le Luduec JB; Shaffer BC; Rajalingam R; Hou L; Hurley CK; Noreen H; Reed EF; Yu N; Vierra-Green C; Haagenson M; Malkki M; Petersdorf EW; Spellman S; Hsu KC
    J Clin Oncol; 2017 Jul; 35(20):2268-2278. PubMed ID: 28520526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients.
    Zhao XY; Chang YJ; Xu LP; Zhang XH; Liu KY; Li D; Huang XJ
    Br J Cancer; 2014 Sep; 111(6):1080-8. PubMed ID: 25077441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of donor KIRs and recipient KIR/HLA class I combinations on GVHD in patients with acute leukemia after HLA-matched sibling HSCT.
    Mansouri M; Villard J; Ramzi M; Alavianmehr A; Farjadian S
    Hum Immunol; 2020 Jun; 81(6):285-292. PubMed ID: 32199702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic role of KIR genes and HLA-C after hematopoietic stem cell transplantation in a patient cohort with acute myeloid leukemia from a consanguineous community.
    Gaafar A; Sheereen A; Almohareb F; Eldali A; Chaudhri N; Mohamed SY; Hanbali A; Shaheen M; Alfraih F; El Fakih R; Iqneibi A; Youniss R; Elhassan T; Hashmi S; Aljurf M; Alhussein K
    Bone Marrow Transplant; 2018 Sep; 53(9):1170-1179. PubMed ID: 29549293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KIR and HLA genotypes predictive of low-affinity interactions are associated with lower relapse in autologous hematopoietic cell transplantation for acute myeloid leukemia.
    Marra J; Greene J; Hwang J; Du J; Damon L; Martin T; Venstrom JM
    J Immunol; 2015 May; 194(9):4222-30. PubMed ID: 25810393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Donor
    Schetelig J; Baldauf H; Heidenreich F; Hoogenboom JD; Spellman SR; Kulagin A; Schroeder T; Sengeloev H; Dreger P; Forcade E; Vydra J; Wagner-Drouet EM; Choi G; Paneesha S; Miranda NAA; Tanase A; de Wreede LC; Lange V; Schmidt AH; Sauter J; Fein JA; Bolon YT; He M; Marsh SGE; Gadalla SM; Paczesny S; Ruggeri A; Chabannon C; Fleischhauer K
    Front Immunol; 2024; 15():1350470. PubMed ID: 38629074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human Leukocyte Antigen-C Genotype and Killer Immunoglobulin-like Receptor-Ligand Matching in Korean Living Donor Liver Transplantation.
    Lee H; Park KH; Park HS; Ryu JH; Lim J; Kim Y; Na GH; Kim DG; Oh EJ
    Ann Lab Med; 2017 Jan; 37(1):45-52. PubMed ID: 27834065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia.
    Schetelig J; Baldauf H; Koster L; Kuxhausen M; Heidenreich F; de Wreede LC; Spellman S; van Gelder M; Bruno B; Onida F; Lange V; Massalski C; Potter V; Ljungman P; Schaap N; Hayden P; Lee SJ; Kröger N; Hsu K; Schmidt AH; Yakoub-Agha I; Robin M
    Front Immunol; 2020; 11():584520. PubMed ID: 33542712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation.
    Bachanova V; Weisdorf DJ; Wang T; Marsh SGE; Trachtenberg E; Haagenson MD; Spellman SR; Ladner M; Guethlein LA; Parham P; Miller JS; Cooley SA
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1602-1607. PubMed ID: 27220262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Status of donor-recipient HLA class I ligands and not the KIR genotype is predictive for the outcome of unrelated hematopoietic stem cell transplantation in beta-thalassemia patients.
    La Nasa G; Littera R; Locatelli F; Giardini C; Ventrella A; Mulargia M; Vacca A; Orrù N; Orrù S; Piras E; Giustolisi G; Lisini D; Nesci S; Caocci G; Carcassi C
    Biol Blood Marrow Transplant; 2007 Nov; 13(11):1358-68. PubMed ID: 17950922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells.
    Verheyden S; Ferrone S; Mulder A; Claas FH; Schots R; De Moerloose B; Benoit Y; Demanet C
    Cancer Immunol Immunother; 2009 Jun; 58(6):855-65. PubMed ID: 18841361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.